Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) EBITDA Margin: 2013-2025

Historic EBITDA Margin for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to -383.14%.

  • Coherus Oncology's EBITDA Margin rose 39108.00% to -383.14% in Q3 2025 from the same period last year, while for Sep 2025 it was -33.36%, marking a year-over-year increase of 16919.00%. This contributed to the annual value of -41.83% for FY2024, which is 3716.00% up from last year.
  • Coherus Oncology's EBITDA Margin amounted to -383.14% in Q3 2025, which was up 13.63% from -443.59% recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's EBITDA Margin peaked at 17.16% during Q4 2024, and registered a low of -2,937.05% during Q1 2024.
  • Over the past 3 years, Coherus Oncology's median EBITDA Margin value was -383.14% (recorded in 2025), while the average stood at -535.41%.
  • In the last 5 years, Coherus Oncology's EBITDA Margin crashed by 272,819bps in 2024 and then surged by 233,914bps in 2025.
  • Coherus Oncology's EBITDA Margin (Quarterly) stood at -53.91% in 2021, then slumped by 5,963bps to -113.54% in 2022, then soared by 3,825bps to -75.29% in 2023, then surged by 9,244bps to 17.16% in 2024, then soared by 39,108bps to -383.14% in 2025.
  • Its EBITDA Margin stands at -383.14% for Q3 2025, versus -443.59% for Q2 2025 and -597.91% for Q1 2025.